microRNA-628 (miR-628)

microRNA-628 (miR-628) is a single-stranded, non-coding small RNA that functions as a post-transcriptional regulator of gene expression by targeting messenger RNA for degradation or translational repression. It is rapidly induced by Toll-like receptor signaling in immune cells and regulates immune and inflammatory responses by targeting genes such as MyD88, a key adaptor in Toll-like receptor pathways, and has been shown to influence NF-κB dependent transcription in monocytes. In oncology, miR-628 negatively regulates cancer cell proliferation, invasion, and migration, and can modulate apoptosis and drug sensitivity, acting as a biomarker and a potential therapeutic tool in prostate and pancreatic cancer among others. The expression and function of miR-628 are subject to physiological regulators such as leptin and inflammatory signals; however, direct targeting by approved drugs or clinical therapies is not currently documented. miR-628 may act as a negative feedback regulator in immune signaling and inflammation by suppressing overactive Toll-like receptor pathways, thereby helping to prevent excessive inflammatory damage. In cancer, miR-628 frequently shows tumor-suppressor-like behavior, with decreased levels associated with increased tumor cell aggressiveness. No standard drugs are known to bind or target miR-628 directly; instead, its levels can influence the response to other cancer drugs in preclinical models. It is not a receptor, enzyme, transporter, or traditional drug target, but a regulatory RNA, so it is not considered a direct "therapeutic target" in the classical sense.

Other names

hsa-miR-628mir-628hsa-mir-628MIRN628MIR628

Post-transcriptional inhibition of target mRNA translation or stability; Modulation of cancer cell sensitivity to chemotherapeutics (e.g., through apoptosis induction in prostate cancer for enzalutamide, docetaxel)